News

Healthcare providers can consider these strategies when developing a plan to transition to more frequent in-office treatment.

Program could be easily implemented at tribal clinics, says lead author.

Paying attention to the social determinants of health may be a powerful way of improving cardiovascular outcomes.

Centralized resource streamlines information sharing between health plans, Medicaid agencies and third-party app developers ahead of CMS Interoperability and Patient Access rule deadlines.

FDA has recently approved therapies targeting MET exon 14 skipping mutations.

Projections of 600-1,400 fewer deaths were set against the risk of 26-45 cases of blood clots.

Dr. Kathleen Bethin, clinical professor, and Dr. Lucy Mastrandrea, associate professor and division chief of endocrinology/diabetes both at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo, spoke with Vic Baldry of Cecelia Health to discuss the challenges telehealth has created when caring for families with children who have type 1 diabetes.

Biomarker status can help clinicians and patients make informed, personalized treatment decisions, whether the choice is an FDA-approved targeted therapy or a clinical trial.

The use of accurate biomarkers for detecting autism spectrum disorder could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research.

But many devices don’t communicate with a patient’s electronic health record.

In this week's episode of "Tuning In to the C-Suite" podcast, Senior Editor Peter Wehrwein spoke with Debra Cooper, RN, MSN, MBA/HCM, a senior risk specialist at Coverys, a medical malpractice insurance company headquartered in Boston. Wehrwein and Cooper discussed the role the company has played in advising providers during the COVID-19 pandemic, risk mitigation, and the role they can now play in overcoming vaccine hesitancy.

Opdivo is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.

The FDA approved proton beam radiation in 1988. But whether it is an improvement over conventional photon radiation as a treatment for many cancers remains an open question.

The Blue Cross Blue Shield Association's new strategy sets their goal to reduce racial disparities in maternal health by 50% in five years.

The four historically Black medical schools are part of the answer as U.S. healthcare reckons with racism and inequity. They are expanding and receiving record levels of donations.

A Medicare Advantage group and other organizations are endorsing legislation that would allow data collected during audio-only visits to be used to set risk adjustment payment levels to MA plans.

The combination monoclonal antibody treatment of bamlanivimab and etesevimab still OK.

Automated texts may also lessen the workload on nurses.

Brooks, senior medical director of Independence Blue Cross in Philadelphia, was a key member of the team that created a health awareness campaign launched earlier this month in cooperation with local radio station WURD and other partners including the Colorectal Cancer Alliance, the Independence Blue Cross Foundation, Penn Medicine, Labcorp, and the Health Care Improvement Foundation. The campaign, called “Go To Know,” sets out to increase colon cancer screenings among African Americans by providing free Fecal immunochemical, or FIT, tests.

A new survey revealed a majority of health organizations have lack of awareness and are unprepared to comply with the ONC's final rule act of information blocking and improving interoperability provisions. Matthew A. Michela, President and CEO, Life Image, shares how to get on board.

In this third part of a three-part series, Steven D. Pearson, M.D., M.Sc., founder and president of ICER talks the drug Inclisiran and its relation to PCSK9 inhibitors.

A recent survey by Scripta Insights shows 96% of consumer are willing to make a prescription change as far as switching their medications, forms and where they fill in order to save money.

The number of participants in the Medicare Shared Savings Program has tapered off, and the Direct Contracting Model may put accountable care organizations at a disadvantage. The National Association of ACOs wants the Biden CMS to make some changes.

In this second part of a three-part series, Steven D. Pearson, M.D., M.Sc., founder and president of ICER addresses if pricing of PCSK9 inhibitors put ICER on the map.